Like every young person, I yearned to go out and make my mark in the world. I had a Pharmacy degree and was working as an assistant pharmacist in one of the top hospitals of Asia. I had big dreams of doing my masters abroad and becoming a clinical pharmacist. They came crashing down when my parents told me they didn’t want to send me abroad.
I got married and moved to the city and started working for a few months only to give it up when I found out I was pregnant. Though I was happy to be a mother, there was a void in my heart. I wanted to pursue a career. I grew restless over the years and took refuge in reading. I read other books and also my pharmacy books. I used to thumb through the Comprehensive Pharmacy Review by Lippincott and wished to clear licensure exams. But that remained just that, a wish. My second kid was born and I kind of settled into the role of an urban housewife. I did volunteer work, some content editing and taught Sunday school to keep myself busy.
I kept poking around to see if I could do something to upgrade myself. I had a liking for psychiatry and enrolled for a master’s program in counselling through distance education. Distance mode was fine with me as I had to take care of my kids. The course books were a good read and I understood why people behave the way they do. Personality assessments through tests were fun as me and my classmates went on a journey of self- discovery. That done, I enrolled for a masters in Pharmacology. Reading up on postgraduate pharmacy topics opened up a whole new world of fields worth exploring.
After a career break for over a decade, I found work in a hospital as a pharmacy and drugstores in-charge and worked in quality and safety upgradation. Sitting in the department surrounded by racks and refrigerators with all kinds of medicines, surgical stuff and implants, I used to wonder about the number of new drugs coming in to treat different diseases. A urologist narrated how a patient wanted a new drug for joint pain and got a prescription for Etodolac. Patients were looking for new remedies and therapies. The needs were plenty and research was trying to keep up with it.
I was eager to learn and signed up for another course, this time in drug safety and regulatory affairs. The world of clinical research opened up as I took module after module online. I started looking for jobs in the field, but the odds were stacked against me as I had no prior experience in clinical research. I clung to hope. No company was willing to take me in. Friends were sympathetic but it was obvious that entry into new careers was next to impossible at my age. I chanced upon the ICON plc website and liked the company profile. I applied and waited – nothing happened.
Not willing to drown in disappointment, I continued to prepare and apply for other suitable jobs. The COVID-19 pandemic was raging across the land and we were under lockdown. A few months later, ICON contacted me. After clearing the interviews, I joined the company as a clinical data coordinator – my dreams did come true! I was thrilled to bits and thanked the Good Lord for the turn of events.
After the onboarding, my joy quickly evaporated when I realized I knew next to nothing about data management. I’m grateful to my colleagues who patiently taught me the various aspects of the job and encouraged me onward.
I log off at the end of the day with a smile, even on difficult days. Another day, something new learned. I enjoy my journey into this new world of clinical research. Mine was a transition from medicine to molecule; from dealing with drugs and devices waiting to be prescribed for a patient, to the world of researching drugs for patients. I’m glad I didn’t give up.
Closing with a poem by Robert Frost:
Two roads diverged in a wood, and I—
I took the one less traveled by,
And that has made all the difference.
If Frost wouldn’t mind, I’d pen another line in here…ICON made all the difference.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel